NYSE: PFEPfizer Inc Stock
PFE Price
$37.28
Fair Value Price
N/A
Market Cap
$207.16B
52 Week Low
$27.88
52 Week High
$43.08
P/E
23.9x
P/B
3.17x
P/S
4.12x
PEG
0.91x
Dividend Yield
4.02%
Revenue
$48.65B
Earnings
$8.69B
Gross Margin
79.9%
Operating Margin
17.41%
Profit Margin
17.9%
Debt to Equity
1.74
Operating Cash Flow
$13B
Beta
0.71
Next Earnings
Feb 2, 2021
Ex-Dividend
Jan 28, 2021
Next Dividend
Mar 5, 2021
Zen Score
High
Medium
Low
46
Industry average
Reasons for this score
PFE ($37.28) is trading below its intrinsic value of $154.81, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
PFE is good value based on its earnings relative to its share price (23.9x), compared to the US market average 31.52x)
Valuation
PFE is good value based on its earnings relative to its share price (23.9x), compared to the US Drug Manufacturers - General industry average (-5.79x)
Valuation
PFE News
Valuation
PFE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.9x
Industry
-5.79x
Market
31.52x
PFE is good value based on its earnings relative to its share price (23.9x), compared to the US market average 31.52x)
Valuation
PFE is good value based on its earnings relative to its share price (23.9x), compared to the US Drug Manufacturers - General industry average (-5.79x)
Valuation
PFE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.17x
Industry
9.92x
Market
56.65x
PFE is good value based on its book value relative to its share price (3.17x), compared to the US market average (56.65x)
Valuation
PFE is good value based on its book value relative to its share price (3.17x), compared to the US Drug Manufacturers - General industry average (9.92x)
Valuation
PFE price to earnings growth (PEG)
For valuing profitable companies with growth potential
PFE is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.91x)
Valuation
PFE's financial health
Profit margin
Revenue
$12.1B
Net Income
$2.2B
Profit Margin
18.1%
PFE's Earnings (EBIT) of $8.47B can safely cover interest payments on company debt ($63.15B)
Financials
PFE's profit margin has decreased (-12.7%) in the last year from (30.6%) to (17.9%)
Financials
Assets to liabilities
Assets
$179.0B
Liabilities
$113.5B
Debt to equity
0.97
PFE's short-term assets ($47.74B) exceed its short-term liabilities ($34.15B)
Financials
PFE's long-term liabilities ($79.33B) exceed its short-term assets ($47.74B)
Financials
PFE's debt has increased relative to shareholder equity (1.74), over the past 5 years ago (1.55)
Financials
PFE's debt to equity ratio (1.74) is considered high
Financials
Cash flow
Operating
$2.1B
Investing
$481.0M
Financing
-$2.8B
PFE's operating cash flow ($12.55B) may not be sufficient to safely service the company's debt ($63.15B)
Financials
Pfizer Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
